Last reviewed · How we verify

NCT06874894: NOAC

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

ENROLLING BY INVITATION Last updated 29 December 2025
What this trial tests

trial in Fibrillation, Atrial in 1,021 participants. Enrolling by invitation.

Timeline
25 May 2022
Primary endpoint
30 August 2026
30 August 2026

Quick facts

Lead sponsorChung-Ang University Hosptial, Chung-Ang University College of Medicine
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment1,021
Start date25 May 2022
Primary completion30 August 2026
Estimated completion30 August 2026
Sites2 locations across South Korea

Conditions studied

Sponsor

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Who can join

18 Months and older, any sex, with Fibrillation, Atrial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibrillation, Atrial

Currently open trials in the same condition.

Other Chung-Ang University Hosptial, Chung-Ang University College of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing